You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Mycophenolate (Mycophenolate Sodium – Myfortic® & Mycophenolate Mofetil – CellCept®)

Find drug coverage information and forms for mycophenolate, by funding source.

What type of drug coverage does the patient have?

Private Insurance

  • Mycophenolate is typically covered by most private insurance plans.
  • Can provide Myfortic DIN 02264579 or CellCept DIN 02237484 to patient to explore coverage through private insurer and if any special authorization forms are required.

Ontario Drug Benefit (ODB) and OHIP+

  • Myfortic is covered under general benefit.
  • CellCept is covered under general benefit.

Trillium Drug Program (TDP)

  • Enrol into TDP if not already enrolled.
  • Myfortic is covered under general benefit.
  • CellCept is covered under general benefit.

Federal Non-Insured Health Benefits (NIHB) Program

  • Prior approval required. Have community pharmacy contact Drug Exception Centre for Exception Drugs Request Form to be sent to prescriber’s office. Send completed form to Drug Exception Centre.

Interim Federal Health Program (IFHP)

  • Medication coverage and duration of coverage vary depending on each individual’s case.
  • Contact IFHP with Myfortic DIN 02264579 or CellCept DIN 02237484 for assessment of coverage.

No Medication Coverage

  • Option to pay cash for medication or enrol into TDP.
  • If enrolling in TDP, refer to TDP.

Disclaimer: The information contained herein (“Information”) is intended for informational purposes only, and no warranty as to its accuracy is provided or implied. The Information was collected from third party sources and is subject to change without notice. Cancer Care Ontario (CCO) makes no warranty that the Information is current. The Information is intended for use by healthcare professionals, subject to their clinical and/or professional judgment, to advise patients of drug funding options that may be available to them. Do not act or rely upon the Information without exercising your independent judgment or seeking the advice of a qualified professional. Anyone using the Information does so at his or her own risk. The drug funding options described herein are managed and funded by third parties, not by CCO. Please direct any inquiries to the applicable agency/entity who manages the drug funding option. CCO does not recommend or endorse the use of any drug or treatment method described herein.